Skip to main content

Market Overview

Pfizer COVID-19 Vaccine Gets Approved In Australia

Share:
Pfizer COVID-19 Vaccine Gets Approved In Australia

The COVID-19 vaccine made by Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) has been approved by Australia’s Therapeutic Goods Administration, Reuters reported Monday (Sydney Time).

What Happened: Inoculation of Pfizer’s vaccine is likely to commence in late February at 80,000 doses per week, Australia’s Health Minister Greg Hunt told reporters.

The New York-based drug multinational reportedly told the Australian government that, while it anticipated continuous supply of the vaccine, it would give global production guidance in mid-February for March and beyond on a weekly basis.

The TGA has approved the Pfizer shot for those aged 16 and above.

Why It Matters: No new cases of community transmissions have been recorded in Australia in the past week and there are no patients receiving intensive care in the country’s hospitals, according to Reuters.

Australia has a target of four million vaccine doses by April and has made commitments of supply to other island nations in the Pacific.

AstraZeneca Plc’s (NASDAQ: AZN) vaccine is still awaiting approval in Australia, but it is expected that CSL will start the domestic supply of that vaccine in March at one million doses a week, according to Hunt.

The international stock of AstraZeneca’s vaccine flowing to Australia would be limited due to the “significant supply shock” experienced by the British drugmaker, Hunt said.

Pfizer’s vaccine has shown efficacy against new strains of COVID-19 that emerged in the United Kingdom and South Africa.

Price Action: Pfizer shares closed nearly 0.2% higher at $36.55 on Friday. On the same day, BioNTech shares closed 2.85% higher at $108.44 and fell 1.05% in the after-hours session to $107.30.

 

Related Articles (PFE + BNTX)

View Comments and Join the Discussion!

Posted-In: Australia Covid-19 vaccineBiotech News Events Media General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com